NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

ORCL gains on strong cloud momentum, while NVO battles obesity headwinds and LIN leans on $10B backlog for growth.

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Investing.com -- The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that ...

Rocket Lab announced the launch window for its next mission, 'The Mountain God Guards,' for the Institute for Q-shu Pioneers of Space.

Dana Simmons wants you to know that if you are hungry, it is not your fault. In her recently released book, “On Hunger: ...